What is the Impact Factor of Nucleic Acid Therapeutics?

According to the latest Clarivate Journal Citation Reports (JCR), the Journal Impact Factor of Nucleic Acid Therapeutics is 4.50, ranking in quartile Q2 of Web of Science (SCIE).

Is Nucleic Acid Therapeutics indexed in Web of Science or Scopus?

Yes, Nucleic Acid Therapeutics is indexed in Web of Science (SCIE, Q2 quartile). Furthermore, in Scopus (SCImago), it holds an SJR rating of 1.950 (Q1) and an H-index of 85.

Who publishes Nucleic Acid Therapeutics and what is the Article Processing Charge (APC)?

Nucleic Acid Therapeutics is published by Mary Ann Liebert Inc.. The estimated Article Processing Charge (APC) is approximately $3,610 USD, subject to institutional waivers and corresponding author affiliations.

What is the ISO-4 abbreviation and acronym of Nucleic Acid Therapeutics?

The official ISO-4 abbreviation of Nucleic Acid Therapeutics is "NUCLEIC ACID THER" with common acronym "nucleicacidtherapeut". This standardized title abbreviation is used in citation lists conforming to IEEE, APA, Harvard, or Vancouver styles.

WoS SCIE Q2Scopus Q1SCImago #1,521Hybrid

Nucleic Acid Therapeutics

Acronym:nucleicacidtherapeut

•

Abbreviation (ISO):NUCLEIC ACID THER

•

Identifier (ISSN):2159-3337(Print)/2159-3345(Online)

•

Publisher:Mary Ann Liebert Inc.

Official Website Submission Portal Compare

Clarivate IF (2026)

4.5↓ -0.2

Journal Impact Factor

IF Trend↓

WoS Quartile

WoS SCIEJCR Quartile

Clarivate WoS JCR

WoS Categories↓

JCR Release Date: 2026-06-17

Impact Factor Trend (2018–2026)

Clarivate IF trend for Nucleic Acid Therapeutics

WoS Q2

Annual Impact Factor Metric

Current (2026):4.5

Scopus SJR & RankScopus Q1

1.95

#1,521

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025

H-Index (2025)

85 papers with at least that number of citations each

WoS: SCIE / JCRQ2

Self-Citation Rate5%

Safe Level (< 15%)Warning Level (> 20%)

Self-citation below 15% indicates strong scholarly independence.

Volume & Open AccessHybrid

40articles/year

36.14% Gold OA•97.56% Original Research

Aims & Scope

Nucleic Acid Therapeutics is the leading journal in its field focusing on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression. The Journal examines many new approaches for using nucleic acids as therapeutic agents or in modifying nucleic acids for therapeutic purposes including: oligonucleotides, gene modification, aptamers, RNA nanoparticles, and ribozymes.

Topics Covered (Recognized by AI)

Biology97.7%Genetics92.9%Chemistry92.1%Biochemistry90.2%Gene81.2%Medicine72.4%Internal medicine54.8%RNA49.4%DNA46.7%Molecular biology44.1%Cell biology35.4%Oligonucleotide34.9%Cell culture33.5%Computational biology30.7%Physics27.6%Organic chemistry26.6%Immunology23.4%Transfection23.4%Pharmacology21.8%

Primary Research Areas

Biochemistry & Molecular Biology Chemistry Medicinal

Official Website NLM PubMed Catalog Submission Portal SCImago Profile

0 calls

Special Issues

Calls for Papers

No active Calls for Papers found for this journal.

Expand

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI

JCRSCIE2026

BIOCHEMISTRY & MOLECULAR BIOLOGY

Rank103/328

IndexSCIE

JCRSCIE2026

CHEMISTRY, MEDICINAL

Rank23/72

IndexSCIE

JCRSCIE2026

MEDICINE, RESEARCH & EXPERIMENTAL

Rank59/191

IndexSCIE

JCISCIE2026

BIOCHEMISTRY & MOLECULAR BIOLOGY

Rank88/328

IndexSCIE

JCISCIE2026

CHEMISTRY, MEDICINAL

Rank24/72

IndexSCIE

JCISCIE2026

MEDICINE, RESEARCH & EXPERIMENTAL

Rank52/191

IndexSCIE

Category	Index	Rank	Quartile
BIOCHEMISTRY & MOLECULAR BIOLOGY	JCRSCIE	103/328	Q2
CHEMISTRY, MEDICINAL	JCRSCIE	23/72	Q2
MEDICINE, RESEARCH & EXPERIMENTAL	JCRSCIE	59/191	Q2
BIOCHEMISTRY & MOLECULAR BIOLOGY	JCISCIE	88/328	Q2
CHEMISTRY, MEDICINAL	JCISCIE	24/72	Q2
MEDICINE, RESEARCH & EXPERIMENTAL	JCISCIE	52/191	Q2

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year

2026Latest

IF4.5

Articles / Year16

Total Citations4

2025

IF4.7

Articles / Year34

Total Citations117

2024

IF4

Articles / Year33

Total Citations285

2023

IF4

Articles / Year26

Total Citations397

2022

IF4.244

Articles / Year42

Total Citations934

Year	Impact Factor	Articles / Year	Total Citations
2026	4.5	16	4
2025	4.7	34	117
2024	4	33	285
2023	4	26	397
2022	4.244	42	934
2021	5.486	42	1,011
2020	4.875	44	1,107
2019	3.78	40	911
2018	2.623	41	2,916
2017	—	33	1,844
2016	—	43	1,683
2015	—	40	925

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #1,521Scopus Q1SCImago Profile

Scopus Coverage:2011-2025

•

Scopus Broad Areas:Biochemistry, Genetics and Molecular BiologyPharmacology, Toxicology and Pharmaceutics

Scopus Citation Rank (SJR)Q1

1.95

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q1

Citations / Doc (2 years)

5.16

Average citations received per document published in the 2-year window.

2-Year Citation Window

Estimated Publication Fee (APC)

$3,610 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations629

3-Year Documents109

Citable Documents106

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)0

Citations in government and international policy documents

Female Author Rate46.2%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

BiochemistryQ1

Drug DiscoveryQ1

GeneticsQ1

Molecular BiologyQ1

Molecular MedicineQ1

Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth

Self-citation: 5%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):

3区 (Zone 3)Medicine

Minor Category (Specific Field):

3区BIOCHEMISTRY & MOLECULAR BIOLOGY

CAS Early Warning List History:

Updated annually: 2020 – 2024

2020

Not warned

2021

Not warned

2022

Not warned

2023

Not warned

2024

Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Nucleic Acid Therapeutics (acronym: nucleicacidtherapeut, abbr: NUCLEIC ACID THER, ISSN: 2159-3337) is a peer-reviewed international scholarly journal in the field of BIOCHEMISTRY & MOLECULAR BIOLOGY, published by Mary Ann Liebert Inc. in United States since 2011. The periodical holds a Journal Impact Factor (JIF) of 4.50, ranking in quartile Q2 of Web of Science (SCIE), a Scopus SJR indicator of 1.950 (Q1), an H-index of 85.

The journal enforces rigorous peer evaluation with an annual output of approximately 40 scientific articles. In terms of accessibility and author fees, it operates under the Hybrid model with an estimated APC of $3,610 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.